15-hydroxy-11-alpha-9-alpha-(epoxymethano)prosta-5-13-dienoic-acid and 5-6-dihydroprostacyclin

The prostaglandins PGE1, PGE2, PGD2, PGF2 alpha, U46619 and 6 beta-PGI1 were administered as bolus injections both separately and in combination with angiotensin II into the fetal circulation of isolated human placental cotyledons perfused in vitro. PGF2 alpha and PGD2 caused small dose-dependent increases in fetal perfusion pressure when compared with U46619 which acted as an extremely potent vasoconstrictor of the fetal-placental vasculature. PGE1 caused very small dose-dependent decreases in fetal perfusion pressure when injected on its own. In combination with angiotensin II, PGE1, PGD2 and 6 beta-PGI1 caused significant, dose-related attenuations of the angiotensin II vasoconstrictive response whereas PGE2, PGF2 alpha and U46619 potentiated the response. Injections of angiotensin II after the infusion of indomethacin into the fetal circulation resulted in a potentiation of angiotensin II induced vasoconstriction. The results indicate that prostaglandins exert their effects on the fetal-placental circulation by modulating the actions of angiotensin II.

Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Alprostadil; Angiotensin II; Dinoprostone; Drug Interactions; Epoprostenol; Female; Humans; In Vitro Techniques; Perfusion; Placenta; Pregnancy; Prostaglandin D2; Prostaglandin Endoperoxides, Synthetic; Prostaglandins; Prostaglandins D; Prostaglandins E; Prostaglandins, Synthetic; Vasoconstriction

Trapidil (N,N-diethyl-5-methyl[1,2,4]triazolo[1,5-alpha]pyrimidine-7-amine ) inhibits platelet spreading and aggregation induced by arachidonic acid (AA), a stable analogue of prostaglandin (PG) endoperoxides (U46619), ADP, and low concentrations of thrombin, but not by A23187 and high concentrations of thrombin. Trapidil does not affect platelet adenylate cyclase but inhibits the cAMP PDE by approx. 50%. PDE inhibition proceeds via a competitive mechanism (Ki = 0.52 mM) and is not mediated by calmodulin inhibition. Trapidil does not change the platelet basal cAMP level but potentiates an increase of cAMP induced by the stable prostacyclin analogue (6 beta-PGI1). These results suggest that trapidil antiplatelet effects may be due to the inhibition of platelet PDE.

Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine Diphosphate; Arachidonic Acid; Arachidonic Acids; Calcimycin; Cyclic AMP; Epoprostenol; Humans; Platelet Adhesiveness; Platelet Aggregation; Prostaglandin Endoperoxides, Synthetic; Pyrimidines; Theophylline; Thrombin; Trapidil

Immunoassays were developed for quantitative determination of thromboxane B2, prostaglandin D2, 13,14-dihydro-prostaglandin E2, 5,6-dihydro-prostaglandin I2, 6-keto-prostaglandin F1 alpha, 15-hydroxy-9 alpha, 11 alpha (epoxymethano) prosta-5, 13-dienoic acid and 15-hydroxy-11 alpha, 9 alpha (epoxymethano) prosta-5,13-dienoic acid. Ligands immobilized by covalent linkage to a solid support, bound homologous rabbit antibodies. [125I] Protein A was used to measure the bound IgG antibody. Increments of homologous and heterologous fluid-phase ligand completed with solid-phase ligand for antibody and resulted in decreasing amounts of bound [125I]-Protein A. The serologic specificity for each immune system was determined. Immunoassays for thromboxane B2, 6-keto-prostaglandin F1 alpha, and 5,6-dihydro-prostaglandin I2 were used to identify their respective homologous ligands that were separated by normal phase and reversed phase high pressure liquid chromatography.

Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 6-Ketoprostaglandin F1 alpha; Animals; Antibody Specificity; Antigen-Antibody Reactions; Dinoprostone; Epoprostenol; Ligands; Prostaglandin Endoperoxides, Synthetic; Prostaglandins; Prostaglandins D; Prostaglandins E, Synthetic; Prostaglandins F; Prostaglandins, Synthetic; Rabbits; Radioimmunoassay; Staphylococcal Protein A; Thromboxane B2